New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Biotechnologies for ...

Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication ...

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits.

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

Sales of the weight loss injection Wegovy have skyrocketed in the UK after the manufacturer of rival drug Mounjaro announced ...